This application constitutes the fifth competitive renewal of The Mount Sinai School of Medicine Alzheimer's Disease Research Center. We have used the strengths of our well established center to address the new vision of the NIA Center program. We have proposed standardized assessment to be used at all our sites and the EITC core will assist us with developing procedures manual, training materials and certification methods to insure that the evaluations can be reliably collected from a range of research staff. The newly established Data Management Core has been intimately involved in the development of the data collection instruments to insure that they can be readily entered into the data warehouse, that clinical and neuropathological information can be accessed and integrated and that the extraction of the NACC data set can be accomplished seamlessly. This submission highlights our long standing accomplishments in clinical evaluation and neuropathological characterization of healthy elderly, mild cognitive impairment and early AD. In project 0023, we will integrate clinical and neuropathological to trace the earliest indicators of cognitive change in aging and dementia. In Projects 0024 and 0028, leading notions of potential etiologic mechanisms are explored in depth. In this renewal the following cores and projects are proposed: 1. Administrative Core A (M. Sano/J. Morrison) 2. Clinical Research Support Core/ Elmhurst Satellite (M. Sano) 3. Data Management Core C (V, Haroutunian) 4. Neuropathology Core D (D.Perl/V.Haroutunian) 5. Education and Information Transfer Core E (M.Sewell/M.Sano) 6. Project #0023: Selective Neuronal Pathology in the Development of Dementia (P. Hof) 7. Project #0024: Identification and characterization of first messengers that regulate APP processing (J. Buxbaum) 8. Project #0028: PS1 Regulates Cleavage and Function of EphrinB ligand and EphB Receptor (A.Georgakopoulos)

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Specialized Center (P50)
Project #
5P50AG005138-25
Application #
7597024
Study Section
Special Emphasis Panel (ZAG1-ZIJ-7 (J4))
Program Officer
Phelps, Creighton H
Project Start
1997-05-01
Project End
2010-04-30
Budget Start
2009-04-15
Budget End
2010-04-30
Support Year
25
Fiscal Year
2009
Total Cost
$1,739,396
Indirect Cost
Name
Icahn School of Medicine at Mount Sinai
Department
Psychiatry
Type
Schools of Medicine
DUNS #
078861598
City
New York
State
NY
Country
United States
Zip Code
10029
Ki?emet-Piska?, Spomenka; Babi? Leko, Mirjana; Blažekovi?, Antonela et al. (2018) Evaluation of cerebrospinal fluid phosphorylated tau231 as a biomarker in the differential diagnosis of Alzheimer's disease and vascular dementia. CNS Neurosci Ther 24:734-740
Soleimani, Laili; Ravona-Springer, Ramit; Heymann, Anthony et al. (2018) Depression is more strongly associated with cognition in elderly women than men with type 2 diabetes. Int Psychogeriatr :1-5
Burke, Shanna L; Maramaldi, Peter; Cadet, Tamara et al. (2018) Decreasing hazards of Alzheimer's disease with the use of antidepressants: mitigating the risk of depression and apolipoprotein E. Int J Geriatr Psychiatry 33:200-211
Audrain, Mickael; Haure-Mirande, Jean-Vianney; Wang, Minghui et al. (2018) Integrative approach to sporadic Alzheimer's disease: deficiency of TYROBP in a tauopathy mouse model reduces C1q and normalizes clinical phenotype while increasing spread and state of phosphorylation of tau. Mol Psychiatry :
Boban, Mirta; Babi? Leko, Mirjana; Miški?, Terezija et al. (2018) Human neuroblastoma SH-SY5Y cells treated with okadaic acid express phosphorylated high molecular weight tau-immunoreactive protein species. J Neurosci Methods :
Zhu, Carolyn W; Grossman, Hillel; Neugroschl, Judith et al. (2018) A randomized, double-blind, placebo-controlled trial of resveratrol with glucose and malate (RGM) to slow the progression of Alzheimer's disease: A pilot study. Alzheimers Dement (N Y) 4:609-616
Qian, Winnie; Fischer, Corinne E; Schweizer, Tom A et al. (2018) Association Between Psychosis Phenotype and APOE Genotype on the Clinical Profiles of Alzheimer's Disease. Curr Alzheimer Res 15:187-194
Davis, Jeremy J (2018) Performance validity in older adults: Observed versus predicted false positive rates in relation to number of tests administered. J Clin Exp Neuropsychol 40:1013-1021
Gallagher, Damien; Kiss, Alex; Lanctot, Krista et al. (2018) Depression and Risk of Alzheimer Dementia: A Longitudinal Analysis to Determine Predictors of Increased Risk among Older Adults with Depression. Am J Geriatr Psychiatry 26:819-827
Silverman, Jeremy M; Schmeidler, James (2018) Outcome age-based prediction of successful cognitive aging by total cholesterol. Alzheimers Dement 14:952-960

Showing the most recent 10 out of 555 publications